menu search

travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney funct...

November 3, 2023, 2:46 pm

travere therapeutics to report third quarter 2023 financial results

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- travere Therapeutics, Inc. (NASDAQ: TVTX) today announced ...

October 24, 2023, 4:30 pm

travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsenta...

October 13, 2023, 8:30 pm

travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsent...

October 13, 2023, 4:30 pm

travere therapeutics to present abstracts at the 17th international symposium on iga nephropathy (iigann 2023)

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- travere Therapeutics, Inc. (NASDAQ: TVTX) today announced...

September 26, 2023, 4:30 pm

travere (tvtx) slumps 41% on mixed results from igan drug study

Data from a confirmatory study shows that travere's (TVTX) IgAN therapy did not achieve one of its conf...

September 22, 2023, 1:31 pm

: travere therapeutics shares plunge as kidney-disease treatment has mixed results in trial

travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data...

September 21, 2023, 4:46 pm

Why shares of travere therapeutics are slumping thursday

travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of...

September 21, 2023, 12:57 pm

travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) — travere Therapeutics, Inc. (NASDAQ: TVTX) today announced...

August 24, 2023, 8:30 pm

travere therapeutics to present abstracts at the society for the study of inborn errors of metabolism annual symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- travere Therapeutics, Inc. (NASDAQ: TVTX) today announced ...

August 24, 2023, 4:30 pm

travere (tvtx) q2 earnings: how key metrics compare to wall street estimates

Although the revenue and EPS for travere (TVTX) give a sense of how its business performed in the quart...

August 3, 2023, 10:31 pm

travere therapeutics (tvtx) reports q2 loss, tops revenue estimates

travere Therapeutics (TVTX) came out with a quarterly loss of $1.13 per share versus the Zacks Consensu...

August 3, 2023, 6:46 pm

Biotech stock travere therapeutics is trading at a deep discount: jpmorgan

travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but ...

July 21, 2023, 2:12 pm

travere therapeutics to report second quarter 2023 financial results

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) — travere Therapeutics, Inc. (NASDAQ: TVTX) today announced...

July 20, 2023, 8:30 pm

travere therapeutics to present at upcoming investor conferences

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- travere Therapeutics, Inc. (NASDAQ: TVTX) today announced ...

June 1, 2023, 4:30 pm

travere: turbulent journey with filspari, downgrading to sell

FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the Phase 3 DUPLEX study raises doubts about its IgAN trial and eventua...

May 29, 2023, 3:49 am

travere therapeutics, inc. (tvtx) q1 2023 earnings call transcript

travere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Compa...

May 7, 2023, 8:14 am

travere therapeutics (tvtx) reports q1 loss, tops revenue estimates

travere Therapeutics (TVTX) came out with a quarterly loss of $1.27 per share versus the Zacks Consensu...

May 4, 2023, 7:01 pm

travere therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug

travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year...

May 2, 2023, 12:50 pm

travere therapeutics announces topline results from two-year primary efficacy endpoint in pivotal phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints tren...

May 1, 2023, 8:05 pm


Search within

Pages Search Results: